Opinion|Videos|April 3, 2025 (Updated: April 3, 2025)
Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
Author(s)Richard S. Finn, MD, Amit Singal, MD
Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows potential beyond first-line treatment, offering efficacy in patients progressing on systemic therapies, with emerging data supporting its role in treatment sequencing.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What treatment considerations arise when a patient progresses and requires second-line therapy?
- Discuss the potential for lenvatinib beyond first-line treatment in patients progressing on systemic therapies.
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.
The phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202) is exploring alisertib plus paclitaxel in small cell lung cancer after immunotherapy and chemotherapy.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
2
SOT106 Receives New FDA FTD and ODD in Sarcoma
3
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
4
IMS 2026 Day 3 Recap: Etentamig Outperforms Standard Therapy in RRMM Trial
5